Dr. Bleickardt has served as a member of our board of directors since March 2020. Since July 2017, Dr. Bleickardt has served as a Global Program Clinical Head for the CAR-T program and member of the Oncology Clinical Development Leadership Team at Novartis. From December 2004 to July 2017, Dr. Bleickardt was at Bristol-Myers Squibb in roles including Early Clinical Development Program Lead and Group Director of Immuno-Oncology Hematology Clinical Development Team. Dr. Bleickardt’s residency was conducted at Beth Israel Deaconess Medical Center/Harvard Medical School and his medical oncology/hematology fellowship at Yale-New Haven Hospital/Yale University School of Medicine. Dr. Bleickardt received his M.D. from University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and his B.S. in Biology from Ursinus College.